Home >> Pharmaceuticals >> Food & Beverage >>

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals

Published: May-2015 | Format: PDF | GlobalData | Number of pages: 104 | Code: MRS - 18236

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2015 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2015 14
2.2.1 AbbVie to Acquire Pharmacyclics for USD21 Billion 14
2.2.2 Actavis Raises USD21 Billion in Public Offering of Senior Notes 15
2.2.3 UnitedHealth to Acquire Catamaran for USD12.8 Billion 15
2.2.4 Valeant Pharma Raises USD10.1 Billion in Private Placement of Senior Notes 15
2.2.5 Teva Pharma to Acquire Auspex Pharma for USD3.2 Billion 16
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2015 17
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2015 18
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19
3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2015 19
3.1.1 Top M&A Deals in March 2015 20
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2014 - March 2015 21
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2015 23
3.2.1 Top Equity Offering Deals in March 2015 24
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2014 - March 2015 25
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2015 27
3.3.1 Top PE/VC Deals in March 2015 28
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2015 29
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2015 30
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, October 2014-March 2015 32
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2014-March 2015 33
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2015 34
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2015 34
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2014 - March 2015 36
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2015 38
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2015 39
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 40
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2014 - March 2015 42
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2014 - March 2015 43
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 45
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2015 47
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2015 47
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2015 49
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2014 - March 2015 51
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2014 - March 2015 53
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2014 - March 2015 55
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2014 - March 2015 58
5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2015 59
5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2015 60
5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2015 61
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 62
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2015 62
6.1.1 Oncology - Deals of the Month 63
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2015 65
6.2.1 Central Nervous System - Deals of the Month 66
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2015 68
6.3.1 Infectious Diseases - Deals of the Month 69
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2015 71
6.4.1 Cardiovascular - Deals of the Month 72
6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2015 74
6.5.1 Immunology - Deal of the Month 75
6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, March 2015 77
6.6.1 Gastrointestinal - Deals of the Month 78
6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2015 80
6.7.1 Metabolic Disorders - Deal of the Month 81
7 Deal Summary by Geography 83
7.1 Pharmaceuticals & Healthcare, North America Deals, March 2015 83
7.1.1 North America - Deals of the Month 84
7.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2015 87
7.2.1 Europe - Deals of the Month 88
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2015 91
7.3.1 Asia-Pacific - Deals of the Month 92
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2015 94
7.4.1 Rest of the World - Deals of the Month 95
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 97
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2014 - March 2015 97
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2014 - March 2015 99
9 Further Information 101
9.1 Methodology 101
9.2 About GlobalData 102
9.3 Disclosure information 103
9.4 Disclaimer 103

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2015 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2015 18
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 20
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2015 20
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2014 - March 2015 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2015 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2015 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2014 - March 2015 29
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2015 31
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 32
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2014 - March 2015 33
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 35
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 37
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 39
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2015 39
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 41
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2014 - March 2015 44
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2014 - March 2015 46
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 48
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 50
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 52
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2015 54
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2014 - March 2015 57
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2015 59
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2015 59
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2015 60
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2015 61
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 63
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 66
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 69
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 72
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 75
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 78
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 81
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 84
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 88
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 92
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 95
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 98
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 100

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2015 17
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2015 18
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 19
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2014 - March 2015 21
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 23
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 25
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 27
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2014 - March 2015 29
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2015 30
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2015 31
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 32
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 34
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 36
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 38
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 40
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2014 - March 2015 42
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2014 - March 2015 43
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 45
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 47
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 49
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 51
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2014 - March 2015 53
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2014 - March 2015 55
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2014 - March 2015 56
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2015 58
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 62
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 65
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 68
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 71
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 74
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 77
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 80
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 83
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 87
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 91
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 94
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 97
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2014 - March 2015 99

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1000 View Pricing